The antibiotic resistance crisis is becoming dire, yet in the past several years few potential antibiotics or adjuvants with novel modes of action have been identified.
Feature of the week #74: Files necessary to share a Monolix run or submit to the regulatory agencies
This video explains the files that need to be included in the regulatory submission or when sharing a run with somebody else.
Repositioning of strongly integrated drugs against achromatopsia (CNGB3)
Achromatopsia (ACHM) is a genetically heterogeneous visual disorder, also known as rod monochromatism, in which human...
Evaluating supersaturation in vitro and predicting its performance in vivo with Biphasic Gastrointestinal Simulator: A case study of a BCS IIB drug
This study aimed to develop an evaluation approach for supersaturation by employing an in vitro bio-mimicking apparatus designed to predict in vivo performance.
Got to Write a Classic: Classical and Perturbation-Based QSAR Methods, Machine Learning, and the Monitoring of Nanoparticle Ecotoxicity
Machine learning has become a central feature in the development or refinement of in silico methodologies and techniques.
Ecotoxicological QSARs of Personal Care Products and Biocides
The personal care products (PCPs) constitute various nonmedical products intended only for the application on the body surface...
A Mechanistic Physiologically-Based Biopharmaceutics Modeling (PBBM) Approach to Assess the In Vivo Performance of an Orally Administered Drug Product: From IVIVC to IVIVP
The application of in silico modeling to predict the in vivo outcome of an oral drug product is gaining a lot of interest.
Feature of the week #73: Typical patterns in the Ovs versus Pred plot
The Obs versus Pred plot is a central tool to diagnose the structural model. This video shows typical deviation patterns and how to interpret them.
A new MAP-Rasagiline conjugate reduces α-synuclein inclusion formation in a cell model
Parkinson’s disease (PD) is the second most common neurodegenerative disease of the elderly.
Modelling pharmacokinetics and pharmacodynamics of the selective S1P 1 receptor modulator cenerimod in healthy subjects and systemic lupus erythematosus patients
Assessment of time to attain steady state as well as drug accumulation following long-term treatment with the selective sphingosine-1-phosphate 1 (S1P1 ) receptor modulator cenerimod and prediction of the incidence of low total lymphocyte (LY) counts.
January 2020 GastroPlus Newsletter
In trying to share the excitement that is building in the SimsPlus development team for the new GPX™ platform… I can only think of the signature Frank Sinatra song “The Best is yet to Come”
Simulations Plus to Present at the 22nd Annual Needham Growth Conference
Simulations Plus to Present at the 22nd Annual Needham Growth Conference
Physiologically based pharmacokinetic modelling of oxycodone drug–drug interactions
Oxycodone is an opioid analgesic with several pharmacologically active metabolites and relatively narrow therapeutic index.
Physiologically based pharmacokinetic modelling of oxycodone drug‐drug interactions
Oxycodone is an opioid analgesic with several pharmacologically active metabolites and relatively narrow therapeutic index.
Application of a hemodialysis clearance prediction model using quantitative structure‐pharmacokinetic relationship analysis
Hemodialysis (HD) is a method used to remove biogenic substances or blood components that cause disease and some drugs...
Simulations Plus Reports Record First Quarter FY2020 Financial Results
First quarter net revenues of $9.4 million reflecting 24.8% year-over-year growth
Feature of the week #72: Display and informativeness of the BLQ data in the plots
To display BLQ data in the plot, Monolix uses simulated BLQ values.
An industrial approach towards solid dosage development for first-in-human studies: Application of predictive science and lean principles
Tablet development is challenging during early clinical phases of drug discovery because of dose uncertainty, limited active pharmaceutical ingredient availability, and short lead times.